[PDF] Top 20 Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients: a propensity analysis
Has 10000 "Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients: a propensity analysis" found on our website. Below are the top 20 most common "Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients: a propensity analysis".
Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients: a propensity analysis
... 210 patients recruited, 146 were matched using propensity scores and included in the comparative ...in patients receiving OXN compared to OXY (increase in Short Form-36 physical component score of ... See full document
10
Efficacy and tolerability of low-dose oral prolonged-release oxycodone/naloxone for chronic nononcological pain in older patients
... All patients provided written informed consent for the collection and analysis of their anonymous demographic and clinical ...inclusion, patients had to meet the following criteria: age 70 years; ... See full document
11
A comparison between the administration of oral prolonged-release oxycodone-naloxone and transdermal fentanyl in patients with moderate-to-severe cancer pain: a propensity score analysis
... methods: Cancer patients with moderate-to-severe chronic pain were con- secutively enrolled in two prospective 28-day trials, received either TDF or OXN-PR, and were assessed at baseline and after 7, 14, ... See full document
11
Analgesic effectiveness and tolerability of oral oxycodone/naloxone and pregabalin in patients with lung cancer and neuropathic pain: an observational analysis
... the efficacy and safety of OXN-PR and pregabalin in cancer patients with neu- ropathic ...and opioid analgesic treatment. The major- ity of patients (82%) achieved the primary endpoint ... See full document
10
Low-dose oral prolonged-release oxycodone/naloxone for chronic pain in elderly patients with cognitive impairment: an efficacy–tolerability pilot study
... elderly patients of the present study, affected on average by multiple ...our patients were all naïve to strong opioids (a requirement for inclusion in the analysis), most of them (89%) were naïve to ... See full document
11
Prolonged-release oxycodone/naloxone reduces opioid-induced constipation and improves quality of life in laxative-refractory patients: results of an observational study
... baseline, patients’ demographic data (age and gen- der), pain condition and previous pain medication (opioids and co-analgesics) were ...documented. Patients’ current laxative regimen, whether the patient ... See full document
11
Quality of life under oxycodone/naloxone, oxycodone, or morphine treatment for chronic low back pain in routine clinical practice
... and patients were aware of the study medication but were blinded to the study end ...for opioid side effects as needed) with improved data analysis due to randomization and blinded end ...adult ... See full document
13
A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients
... Results: A total of 62 patients participated and 53 patients completed the study. Good anal- gesia was obtained for all 4 opioids, for both nociceptive and neuropathic pain. The use of co-analgesics was ... See full document
11
A comparison of the respiratory effects of oxycodone versus morphine: a randomised, double-blind, placebo-controlled investigation
... 1-2 patients, weighing 45-100 kg and /or body mass index BMI < 30 gave informed consent and were randomised to one of the five groups in Table ...1. Patients with previous history of anaesthetic ... See full document
15
Developments in managing severe chronic pain: role of oxycodone–naloxone extended release
... reduce patients’ quality of ...in patients with advanced cancer and older than 65 ...in patients whose pain is not responsive to initial therapies with paracetamol and/or nonsteroidal ... See full document
6
Dietary Supplementation with Omega-3 Polyunsaturated Fatty Acids Reduces Opioid-
... associated with the opioid extinction phase compared to the oxycodone maintenance phase in one or both 378. diets[r] ... See full document
22
The use of rotation to fentanyl in cancer-related pain
... to cancer and heart diseases, being a major symptom in most neoplastic ...in patients suffering from cancer and experiencing a high level of ...pain. Opioid treatment starts with a gradual ... See full document
8
Oxycodone for cancer-related pain.
... CR oxycodone and CR morphine, respectively, within a median of 2 days for both groups (ranges were 1 to 10 and 1 to 9 days, ...CR oxycodone and CR mor- phine patients, respectively, rated the ... See full document
118
Analgesic efficacy and safety of epidural oxycodone in patients undergoing total hip arthroplasty: a pilot study
... The mean duration of postoperative analgesia equaled 10.3±4.89 hours (minimum 5 hours, maximum over 24 hours). One patient did not need administration of a mor- phine rescue dose and his pain scores were <4 according ... See full document
7
Linking altered central pain processing and genetic polymorphism to drug efficacy in chronic low back pain
... The combination of phenotyp- ing disturbances in pain processing and genotyping pre- disposition to pain and polymorphism in drug metabolism may offer the perspective of a more specific treatment of chronic ... See full document
7
Intractable restless legs syndrome: role of prolonged-release oxycodone–naloxone
... the oxycodone–naloxone PR group compared to 43% of the placebo group, while 57% of patients reported at least one adverse event related to treatment during the extension ...of patients in the ... See full document
9
<p>Tapentadol: an effective option for the treatment of back pain</p>
... the patients reported a significant improvement of pain intensity and QoL at last follow-up, and, remarkably, no rel- evant safety concerns were ...of oral tapentadol PR for the treatment of chronic ... See full document
8
Restless legs syndrome: a new entity of neuropathic pain? Treatment with prolonged release oxycodone/naloxone combination
... term benefit is assessed in comparative studies of dopamin- ergic drugs. A further step to optimize indications of RLS management with opioids will be the individuation of poten- tially responder patients, ... See full document
5
A Comparison of Patient-Controlled Analgesia with Oxycodone and Morphine After Total Abdominal Hysterectomy Surgery
... Pasero Opioid-induced Sedation Scale, POSS (S=sleep and easily aroused, 1= awake and alert, 2= slightly drowsy, easily aroused, 3= frequently drowsy, arousable, drifts off to sleep during conversation, 4= ... See full document
6
Switching to low-dose oral prolonged-release oxycodone/naloxone from WHO-Step I drugs in elderly patients with chronic pain at high risk of early opioid discontinuation
... this analysis in patients aged $75 years, one- fifth of whom were older than 85 years, indicate that the fixed combination of strong opioid agonist–antagonist at low dose can be used ... See full document
9
Related subjects